NCT02574637 2021-05-26
Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease
AstraZeneca
Phase 2 Terminated
AstraZeneca
National Institutes of Health Clinical Center (CC)
McGill University Health Centre/Research Institute of the McGill University Health Centre
Sorlandet Hospital HF
Nantes University Hospital